Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 10/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 10/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HRH2 | P25021 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | PTGES | O14684 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30412772 | 1.00 | ADORA1 (0.67) | ADORA1ADORA2AKMT2AHRH2HRH3 | |
| SCHEMBL2329404 | 0.89 | ADORA1 (0.69) | ADORA1ADORA2AKMT2AADORA2B | |
| SCHEMBL2329060 | 0.89 | ADORA1 (0.56) | ADORA1ADORA2AKMT2AHRH2HRH3 | |
| SCHEMBL17667855 | 0.84 | ADORA2A (0.55) | ADORA1ADORA2AKMT2AHRH2HRH3 | |
| SCHEMBL2322814 | 0.83 | ADORA2A (0.73) | ADORA1ADORA2AADORA2B | |
| SCHEMBL2321625 | 0.80 | ADORA2A (1.00) | ADORA1ADORA2AADORA2B | |
| SCHEMBL21852751 | 0.80 | ALDH1A1 (0.67) | ADORA1ADORA2AKMT2AKDM4EALDH1A1 | |
| SCHEMBL13108714 | 0.79 | ALDH1A1 (0.56) | ADORA1KMT2AKDM4EALDH1A1LMNA | |
| Anitrazafen SCHEMBL43419 | 0.79 | ALDH1A1 (0.53) | ADORA1ADORA2AKMT2AKDM4EALDH1A1 | |
| Anitrazafen SCHEMBL30901204 | 0.79 | ALDH1A1 (0.53) | ADORA1ADORA2AKMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054472-B2 | 1,2,4-triazine-4-amine derivatives | NXERA PHARMA UK LIMITED (GB) | 2024-08-06 | — | — | US | disclosed |
| EP-3002280-B1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIV GREENWICH (GB) | 2023-05-24 | — | — | EP | disclosed |
| US-20230021177-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | NXERA PHARMA UK LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| US-10988455-B2 | 1,2,4-triazine-4-amine derivatives | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-04-27 | — | — | US | disclosed |
| US-20190047978-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | NXERA PHARMA UK LIMITED (GB) | 2019-02-14 | — | — | US | disclosed |
| US-10112923-B2 | 1,2,4-triazine-4-amine derivatives | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-10-30 | — | — | US | disclosed |
| US-9862691-B2 | Cyclic triazo and diazo sodium channel blockers | UNIVERSITY OF GREENWICH (GB) | 2018-01-09 | — | — | US | disclosed |
| US-20170291888-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | NXERA PHARMA UK LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| US-20160311784-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIVERSITY OF GREENWICH (GB) | 2016-10-27 | — | — | US | disclosed |
| US-9422253-B2 | Cyclic triazo and diazo sodium channel blockers | UNIVERSITY OF GREENWICH (GB) | 2016-08-23 | — | — | US | disclosed |
| US-8053573-B2 | Monomer 5, 6-diphenyl-1.2.4-traizinic derivatives and the use thereof | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2011-11-08 | — | — | US | disclosed |
| US-8053573-B2 | Monomer 5, 6-diphenyl-1.2.4-traizinic derivatives and the use thereof | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2011-11-08 | — | — | US | disclosed |
| WO-2011095625-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | HEPTARES THERAPEUTICS LIMITED (GB) | 2011-08-11 | — | — | WO | disclosed |
| US-20110009413-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIVERSITY OF GREENWICH (GB) | 2011-01-13 | — | — | US | disclosed |
| EP-2229371-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | University of Greenwich (GB) | 2010-09-22 | — | — | EP | disclosed |
| EP-1751122-B1 | MONOMER 5,6-DIPHENYL-1,2,4-TRIAZINIC DERIVATIVES AND THE USE THEREOF | FABRE PIERRE DERMO COSMETIQUE (FR) | 2010-03-17 | — | — | EP | disclosed |
| WO-2009090431-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIVERSITY OF GREENWICH (GB) | 2009-07-23 | — | — | WO | disclosed |
| US-20080299055-A1 | Monomer 5, 6-Diphenyl-1.2.4-Traizinic Derivatives and the Use Thereof | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2008-12-04 | — | — | US | disclosed |
| US-20080299055-A1 | Monomer 5, 6-Diphenyl-1.2.4-Traizinic Derivatives and the Use Thereof | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2008-12-04 | — | — | US | disclosed |
| US-20080299055-A1 | Monomer 5, 6-Diphenyl-1.2.4-Traizinic Derivatives and the Use Thereof | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080299055-A1 | Monomer 5, 6-Diphenyl-1.2.4-Traizinic Derivatives and the Use Thereof | POT1, TELO2, CLIC1 | ADORA1 721/4885ADORA2A 2069/4885KMT2A 4361/4885 |
| US-20190047978-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | ADORA1 3/4885ADORA2A 2/4885KMT2A 1821/4885 |
| US-20110009413-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | CACNA1E, SCN2B, SCN3A | ADORA1 775/4885ADORA2A 806/4885KMT2A 3049/4885 |
| US-10988455-B2 | 1,2,4-triazine-4-amine derivatives | ADORA2B, ADORA2A, ADORA1 | ADORA1 3/4885ADORA2A 2/4885KMT2A 1821/4885 |
| US-20230021177-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | ADORA1 3/4885ADORA2A 2/4885KMT2A 1680/4885 |
| US-10112923-B2 | 1,2,4-triazine-4-amine derivatives | ADORA2B, ADORA2A, ADORA1 | ADORA1 3/4885ADORA2A 2/4885KMT2A 1799/4885 |
| US-12054472-B2 | 1,2,4-triazine-4-amine derivatives | ADORA2A, ADORA2B, ADORA1 | ADORA1 3/4885ADORA2A 1/4885KMT2A 1685/4885 |
| US-20170291888-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | PTGER1, LTB4R2, LTB4R | ADORA1 19/4885ADORA2A 29/4885KMT2A 1931/4885 |
| US-20160311784-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | SCN1A, SCN1B, SCN3A | ADORA1 217/4885ADORA2A 373/4885KMT2A 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.